4DMedical renews 3-year contract with University of Michigan

18 July 2025

Highlights

- University of Michigan Medical Center, one of the leading academic medical centres in the U.S., has signed a three-year contract renewal valued at approximately AUD$155,000
- The contract allows for University of Michigan clinicians and researchers to use the full suite of 4DMedical's structural lung analysis products, including LDAi, LDAf, PHA, and investigational use of LTA
- Separately, a multicentre trial involving U.S. Veterans, published in Respiratory Research, further demonstrates the unique power of 4DMedical's functional biomarkers
- AEA grant secures AUD$3.8m to advance AI lung function analysis with the University of Melbourne, University of Adelaide, and Australian Institute for Machine Learning

---

Melbourne, Australia, 18 July 2025 – 4DMedical Limited (ASX: 4DX, "4DMedical" or the "Company") a global leader in respiratory imaging technology, is pleased to announce the renewal of its contract with the University of Michigan Medical Center, one of the leading academic medical centres in the United States, for a further three-year term.

Renewal of contract with University of Michigan

Under the renewed contract, which runs from 1 July 2025 to 30 June 2028, 4DMedical will provide University of Michigan clinicians and researchers with access to its full suite of structural lung analysis applications via the Enterprise Core Computing Platform (CCP).

Included in the subscription are the following applications:

- CT Lung Density Analysis – Inspiration (LDAi)
- CT Lung Density Analysis – Functional (LDAf)
- Pulmonary Hypertension Analysis (PHA)
- Lung Texture Analysis (LTA) - investigational use, subject to FDA clearance

This contract highlights 4DMedical's continued traction with leading US institutions and underscores the value placed by the University of Michigan on 4DMedical's suite of structural lung analysis tools in the diagnosis and monitoring of pulmonary diseases.

The contract has a total value of approximately AUD$155,000 over three years.

Recent clinical publications further demonstrate power of 4DMedical technology

In addition to the contract renewal, 4DMedical welcomes the recent publication of a major new multicentre study in ***Respiratory Research*** (July 2025), which demonstrated that 4DMedical's X-ray Velocimetry Lung Ventilation Analysis Software (XV LVAS®) can detect early and subtle forms of small airways disease that are often missed by standard tests like spirometry and CT scans. Researchers from Vanderbilt University, Johns Hopkins, University of Miami, and Alfred Hospital in Melbourne showed that XV Technology® identifies disease-specific and severity-specific biomarker patterns in chronic obstructive pulmonary disease (COPD) and deployment-related constrictive bronchiolitis (DR-CB), even when conventional tests appear normal.

The study showed that XV LVAS®, which produces detailed, region-specific maps of lung ventilation, offered actionable insights for optimised patient care and could reduce the need for invasive lung biopsy. The XV LVAS®-based DR-CB biomarker differentiated patients and revealed unique functional biomarker signatures for each disease.

Study co-leader, Bradley Richmond, M.D., Ph.D., Vanderbilt University Medical Center, commented, "We're now able to see the invisible. XV Technology® gives us a window into parts of the lung we've never been able to assess so precisely before. It could transform care for patients whose symptoms were previously a mystery."

4DMedical awarded $1.1 million in non-dilutive cash funding through AEA grant

4DMedical is pleased to announce that it has been awarded AUD$1.1 million in non-dilutive cash funding under Round 1 of Australia's Economic Accelerator (AEA) Innovate grant program.

The project is led by the University of Adelaide with partners including 4DMedical, the University of Melbourne, and the Australian Institute for Machine Learning. Using XV Technology®, the project will develop novel AI-derived functional biomarkers to enhance respiratory disease diagnosis and treatment.

The Hon Jason Clare MP, Minister for Education, said "These investments allow our world-class universities and researchers to work on game-changing projects that are good for our economy and good for Australia. This is a strategic investment that will help to deliver the solutions we need for the challenges ahead."

4DMedical MD/CEO and Founder Andreas Fouras said:

The University of Michigan is a valued partner, and we are delighted to extend that relationship through this renewal. Their ongoing commitment to our technology reflects the trust major institutions place in 4DMedical's solutions and their recognition of the clinical value delivered through scalable, automated lung analysis.

The biomarkers derived from XV LVAS® findings are game-changing for the field of pulmonary imaging. We are entering a new era where 'the gold standard' for lung disease evaluation will include quantitative, reproducible metrics such as the DR-CB biomarker alongside traditional radiological reads. This body of work exemplifies how functional imaging can not only enhance clinical decision-making, but also elevate the standard of care for patients around the world.

The AEA grant delivers powerful, non-dilutive, leverage on our current R&D investment and accelerates our progress. This grant is a big win for making our technology more accessible and impactful globally.

–ENDS–

Authorised by the 4DMedical Board of Directors.

Contacts

Corporate
Investor Relations
investor.relations@4dmedical.com

Administration
Company Secretary
companysecretary@4dmedical.com

Media Enquiries
4Dmedia@4dmedical.com

About 4DMedical

4DMedical Limited (ASX:4DX) is a cutting-edge global medical technology company revolutionizing respiratory care. By harnessing advanced imaging and AI-powered solutions, 4DMedical delivers unprecedented insights into lung function, enabling earlier and more precise diagnoses of respiratory diseases.

At the heart of 4DMedical's innovation is its patented XV Technology®, a groundbreaking platform that dynamically quantifies ventilation throughout the lungs as patients breathe. This technology underpins the company's FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS®) and its CT LVAS™, empowering physicians to detect and monitor regional airflow abnormalities with unparalleled sensitivity.

4DMedical's solutions integrate seamlessly into existing hospital infrastructure via its Software as a Service (SaaS) model, transforming routine imaging into powerful diagnostic tools.

In December 2023, 4DMedical expanded its leadership in medical imaging with the acquisition of **Imbio**, a pioneer in artificial intelligence solutions for chronic lung and cardiothoracic diseases. Imbio's AI-driven platforms enhance physician productivity, improve diagnostic precision, and support personalized care, aligning seamlessly with 4DMedical's mission to redefine respiratory healthcare.

To learn more, please visit www.4dmedical.com